Y Intercept Hong Kong Ltd bought a new position in QuidelOrtho Corporation (NASDAQ:QDEL – Free Report) during the first quarter, HoldingsChannel reports. The firm bought 48,087 shares of the company’s stock, valued at approximately $790,000.
Several other hedge funds have also bought and sold shares of QDEL. Royal Bank of Canada increased its stake in QuidelOrtho by 1,218.7% during the 1st quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock valued at $2,803,000 after purchasing an additional 74,112 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in QuidelOrtho by 10.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock worth $7,987,000 after buying an additional 21,968 shares during the last quarter. Focus Partners Wealth lifted its stake in shares of QuidelOrtho by 210.9% in the first quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock valued at $715,000 after buying an additional 13,876 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of QuidelOrtho in the second quarter valued at $1,313,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of QuidelOrtho by 250.7% during the second quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock valued at $93,000 after buying an additional 2,309 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have recently commented on QDEL. Zacks Research raised shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Wall Street Zen raised shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. UBS Group reiterated a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research note on Thursday, May 7th. JPMorgan Chase & Co. boosted their price objective on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a report on Wednesday, July 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $13.62.
QuidelOrtho Stock Performance
Shares of QuidelOrtho stock opened at $18.27 on Monday. QuidelOrtho Corporation has a 1 year low of $9.92 and a 1 year high of $35.58. The firm has a market cap of $1.25 billion, a PE ratio of -1.03 and a beta of 0.69. The stock has a fifty day moving average price of $13.65 and a 200-day moving average price of $19.48. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80.
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The company had revenue of $619.80 million during the quarter, compared to analysts’ expectations of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.QuidelOrtho’s quarterly revenue was down 10.5% compared to the same quarter last year. During the same period last year, the firm posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities research analysts anticipate that QuidelOrtho Corporation will post 1.87 EPS for the current year.
QuidelOrtho Profile
QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.
The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.
See Also
- Five stocks we like better than QuidelOrtho
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Corporation (NASDAQ:QDEL – Free Report).
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
